Advancing management of hypertension through pharmacogenomics

Annals of Medicine

Volumn 44, Issue SUPPL. 1, 2012, Pages

  Johnson, Julie A ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Antihypertensive drugs; beta blockers; calcium channel blockers; genetics; pharmacogenetics; pharmacogenomics; thiazide diuretics

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; PROTEIN NEDD4L; RECEPTOR SUBUNIT; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

BLOOD PRESSURE REGULATION; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; HUMAN; HYPERTENSION; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE;

BLOOD PRESSURE; CALCIUM CHANNELS, L-TYPE; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; HUMANS; HYPERTENSION; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA-1; UBIQUITIN-PROTEIN LIGASES;

EID: 84862579604     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2011.653399     Document Type: Review

References (39)

1. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents [see comments] [published erratum appears in N Engl J Med. 1994;330:1689]. N Engl J Med. 1993;328:914-21. (Pubitemid 23086643)
2. Centers for Disease Control and Prevention (CDC). Vital signs: prevalence, treatment, and control of hypertension - United States, 1999-2002 and 2005-2008. MMWR Morb Mortal Wkly Rep. 2011;60:103-8.
3. Ma J, Stafford RS. Screening, treatment, and control of hypertension in US private physician offices, 2003-2004. Hypertension. 2008;51:1275-81. (Pubitemid 351555937)
4. Mori H, Ukai H, Yamamoto H, Saitou S, Hirao K, Yamauchi M, et al. Current status of antihypertensive prescription and associated blood pressure control in Japan. Hypertens Res. 2006;29:143-51.
5. Rodriguez-Roca GC, Pallares-Carratala V, Alonso-Moreno FJ, Escobar-Cervantes C, Barrios V, Llisterri JL, et al. Blood pressure control and physicians' therapeutic behavior in a very elderly Spanish hypertensive population. Hypertens Res. 2009;32:753-8.
6. Thoenes M, Neuberger HR, Volpe M, Khan BV, Kirch W, Bohm M. Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens. 2010;24:336-44.
7. Turner ST, Schwartz GL, Chapman AB, Beitelshees AL, Gums JG, Cooper-DeHoff RM, et al. Plasma renin activity predicts blood pressure responses to [beta]-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens. 2010;23:1014-22.
8. Konoshita T; Investigators tGDOCS. Do genetic variants of the renin-angiotensin system predict blood pressure response to renin-angiotensin system-blocking drugs? A systematic review of pharmacogenomics in the renin-angiotensin system. Curr Hypertens Rep. 2011;13:356-61.
9. Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478:103-9.
10. Fox ER, Young JH, Li Y, Dreisbach AW, Keating BJ, Musani SK, et al. Association of genetic variation with systolic and diastolic blood pressure among African Americans: the Candidate Gene Association Resource study. Hum Mol Genet. 2011;20:2273-84.
11. Kato N, Takeuchi F, Tabara Y, Kelly TN, Go MJ, Sim X, et al. Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. Nat Genet. 2011;43:531-8.
12. Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, et al. Genome-wide association study of blood pressure and hypertension. Nat Genet. 2009;41:677-87.
13. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet. 2009;41:666-76.
14. Wain LV, Verwoert GC, O'Reilly PF, Shi G, Johnson T, Johnson AD, et al. Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet. 2011;43:1005-11.
15. Johnson AD, Newton-Cheh C, Chasman DI, Ehret GB, Johnson T, Rose L, et al. Association of hypertension drug target genes with blood pressure and hypertension in 86,588 individuals. Hypertension. 2011;57:903-10.
16. Johnson JA, Liggett SB. Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions. Clin Pharmacol Ther. 2011;89:366-78.
17. Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, Pauly DF. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther. 2003;74:44-52. (Pubitemid 36776175)
18. Liu J, Liu ZQ, Yu BN, Xu FH, Mo W, Zhou G, et al. beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin Pharmacol Ther. 2006;80:23-32. (Pubitemid 43946840)
19. Shin J, Johnson JA. Pharmacogenetics of beta-blockers. Pharmacotherapy. 2007;27:874-87.
20. Filigheddu F, Reid JE, Troffa C, PinnaParpaglia P, Argiolas G, Testa A, et al. Genetic polymorphisms of the beta-adrenergic system: association with essential hypertension and response to beta-blockade. Pharmacogenomics J. 2004; 4:154-60. (Pubitemid 38786553)
21. Suonsyrja T, Donner K, Hannila-Handelberg T, Fodstad H, Kontula K, Hiltunen TP. Common genetic variation of beta1- and beta2-adrenergic receptor and response to four classes of antihypertensive treatment. Pharmacogenet Genomics. 2010;20:342-5.
22. Pacanowski MA, Gong Y, Cooper-Dehoff RM, Schork NJ, Shriver MD, Langaee TY, et al. beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clin Pharmacol Ther. 2008;84:715-21.
23. Lemaitre RN, Heckbert SR, Sotoodehnia N, Bis JC, Smith NL, Marciante KD, et al. [beta]1- and [beta]2-Adrenergic receptor gene variation, [beta]-blocker use and risk of myocardial infarction and stroke. Am J Hypertens. 2008; 21:290-6. (Pubitemid 351323282)
24. Niu Y, Gong Y, Langaee TY, Davis HM, Elewa H, Beitelshees AL, et al. Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES). Circ Cardiovasc Genet. 2010;3:548-55.
25. Shi PP, Cao XR, Sweezer EM, Kinney TS, Williams NR, Husted RF, et al. Salt-sensitive hypertension and cardiac hypertrophy in mice deficient in the ubiquitin ligase Nedd4-2. Am J Physiol Renal Physiol. 2008;295: F462-70.
26. Dahlberg J, Nilsson LO, von Wowern F, Melander O. Polymorphism in NEDD4L is associated with increased salt sensitivity, reduced levels of P-renin and increased levels of Nt-proANP. PLoS One. 2007;2:e432.
27. Luo F, Wang Y, Wang X, Sun K, Zhou X, Hui R. A functional variant of NEDD4L is associated with hypertension, antihypertensive response, and orthostatic hypotension. Hypertension. 2009;54:796-801.
28. Russo CJ, Melista E, Cui J, DeStefano AL, Bakris GL, Manolis AJ, et al. Association of NEDD4L ubiquitin ligase with essential hypertension. Hypertension. 2005;46: 488-91. (Pubitemid 41376827)
29. Zheng X, Morrison AC, Feingold E, Turner ST, Ferrell RE. Association between NEDD4L gene and sodium lithium countertransport. Am J Hypertens. 2011;24:145-8.
30. Svensson-Farbom P, Wahlstrand B, Almgren P, Dahlberg J, Fava C, Kjeldsen S, et al. A functional variant of the NEDD4L gene is associated with beneficial treatment response with beta-blockers and diuretics in hypertensive patients. J Hypertens. 2011;29:388-95.
31. Johnson JA, Boerwinkle E, Zineh I, Chapman AB, Bailey K, Cooper-Dehoff RM, et al. Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J. 2009;157:442-9.
32. Ishigami T, Araki N, Umemura S. Human Nedd4L rs4149601 G allele generates evolutionary new isoform I with C2 domain. Hypertension. 2010;55:e10; author reply e1.
33. Turner ST, Bailey KR, Fridley BL, Chapman AB, Schwartz GL, Chai HS, et al. Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension. 2008;52:359-65.
34. Hiltunen TP, Suonsyrja T, Hannila-Handelberg T, Paavonen KJ, Miettinen HE, Strandberg T, et al. Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study). Am J Hypertens. 2007;20:311-8.
35. The Nordic Diltiazem Study (NORDIL). A prospective intervention trial of calcium antagonist therapy in hypertension. Blood Press. 1993;2:312-21.
36. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366: 895-906. (Pubitemid 41265663)
37. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805-16. (Pubitemid 37509488)
38. Sherva R, Ford CE, Eckfeldt JH, Davis BR, Boerwinkle E, Arnett DK. Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in relation to antihypertensive treatment. Stroke. 2011;42:330-5.
39. Brugts JJ, Isaacs A, Boersma E, van Duijn CM, Uitterlinden AG, Remme W, et al. Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease. Eur Heart J. 2010;31:1854-64.